492472-30-7|SN-28049|N-(2-(dimethylamino)ethyl)-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b][1,6]naphthyridine-4-carboxamide|-范德生物科技公司

SN-28049

NMR下载 COA and HPLC MSDS下载
names：
N-(2-(dimethylamino)ethyl)-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b][1,6]naphthyridine-4-carboxamide
CAS号：
492472-30-7
MDL Number：
MF(分子式)： C19H22N4O2 MW(分子量)： 338.4
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	N-(2-(dimethylamino)ethyl)-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b][1,6]naphthyridine-4-carboxamide
英文别名	SN28049; SN28049; SN 28049
CAS号	492472-30-7
Inchi	InChI=1S/C19H22N4O2/c1-12-6-5-7-13-10-14-17(21-16(12)13)15(11-23(4)19(14)25)18(24)20-8-9-22(2)3/h5-7,10-11H,8-9H2,1-4H3,(H,20,24)
InchiKey	CSMRPIFORJZYCJ-UHFFFAOYSA-N
分子式 Formula	C19H22N4O2
分子量 Molecular Weight	338.4
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	SN-28049(CAS:492472-30-7):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	SN-28049 SN is a DNA intercalating drug that binds selectively to GC-rich DNA and shows curative activity against the Colon 38 adenocarcinoma in mice. SN 28049 has a complex action that may involve poisoning of topo IIalpha, suppression of topo I and inhibition of gene transcription from promoters with SP-1 sites. These actions may contribute to the promising experimental solid tumour anticancer activity of SN 28049.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Lukka PB, Paxton JW, Kestell P, Baguley BC. Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics. Cancer Chemother Pharmacol. 2012 Jul;70(1):151-60. doi: 10.1007/s00280-012-1892-0. Epub 2012 Jun 3. PubMed PMID: 22660735.

[2]Lukka PB, Paxton JW, Atwell GJ, Kestell P, Baguley BC. A rapid LC-MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: application to in vivo pharmacokinetic and lipophilicity studies in drug development. J Pharm Biomed Anal. 2012 Apr 7;6

[3]9-16. doi: 10.1016/j.jpba.2012.01.022. Epub 2012 Jan 28. PubMed PMID: 22361659.

[4]Chen YY, Finlay GJ, Kirker JA, Marshall ES, Richardson E, Baguley BC. In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma. Invest New Drugs. 2011 Dec;29(6):1504-10. doi: 10.1007/s10637-010-9509-0. Epub 2010 Aug 10. PubMed PMID: 20697772.

[5] Drummond CJ, Finlay GJ, Broome L, Marshall ES, Richardson E, Baguley BC. Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide. Invest New Drugs. 2011 Oct;29(5):1102-10. doi: 10.1007/s10637-010-9473-8. Epub 2010 Jun 22. PubMed PMID: 20567995.

5: Lukka PB, Paxton JW, Kestell P, Baguley BC. Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. Cancer Chemother Pharmacol. 2010 May;65(6):1145-52. doi: 10.1007/s00280-009-1123-5. Epub 2009 Sep 23. PubMed PMID: 19774378.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开